RxDoctor Payments Data

John Kallianos, MD

Internal Medicine · Durham, NCNPI 1245231588

Payments from drug & device makers

$8,381in general payments, 2019–2025

Across 498 payments — averaging $16.83 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$1K
  • Pfizer$929
  • AbbVie$735
  • Boehringer Ingelheim$708
  • Lilly USA, LLC$706
  • AstraZeneca$399
  • plus $4K from 43 others

What the payments were for

  • Food & beverage$8,346100%
  • Education$350%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$8,381 in reported general payments places this provider in the 90th percentile of 3,302 internal medicine providers in North Carolina.

See all internal medicine providers in North Carolina

Medicare billing

Part B allowed, 2024
$168,748
Medicare patients
432
Services billed
12,536

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban276$201,904
JardianceEmpagliflozin128$144,248
OzempicSemaglutide110$111,976
XareltoRivaroxaban73$73,194
JanuviaSitagliptin Phosphate43$58,258
Trelegy ElliptaFluticasone/Umeclidin/Vilanter77$52,065
Tresiba Flextouch U-200Insulin Degludec33$31,730
RybelsusSemaglutide20$30,496
RexultiBrexpiprazole20$27,983
LinzessLinaclotide35$27,010
FarxigaDapagliflozin Propanediol32$26,115
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog29$17,687
MounjaroTirzepatide19$17,633
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr24$13,558
TrulicityDulaglutide14$12,951

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$929$201,904276 claims
Boehringer IngelheimJardiance, Spiriva Respimat$708$152,824141 claims
Novo NordiskOzempic, Rybelsus$1,109$142,472130 claims
GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta, Shingrix$210$84,805167 claims
Johnson & JohnsonXarelto$242$73,19473 claims
MerckJanuvia$201$58,25843 claims
AbbVieLinzess, Synthroid$735$33,433131 claims
Lilly USA, LLCMounjaro, Trulicity$706$30,58433 claims
Otsuka America Pharmaceutical, Inc.Rexulti$135$27,98320 claims
AstraZenecaFarxiga$399$26,11532 claims
Sanofi-aventis U.S. LLCLantus$333$6,02822 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCTrulance$149$5,83511 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 3,302 internal medicine providers in North Carolina.

Other internal medicine in Durham

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →